1型糖尿病患者的体重循环与糖尿病肾病风险:DCCT/EDIC人群研究
该研究对DCCT/EDIC研究中1432例1型糖尿病患者进行回顾性分析,计算体重变异指数(以VIM为主要指标),随访21±4年。结果显示高VIM与eGFR较基线下降40%、血清肌酐翻倍、CKD 3期及eGFR年下降>3 mL/min/m2的发生率显著相关,校正随访协变量后与白蛋白尿的关联未保持显著。
要点
- 高体重变异指数(VIM)与eGFR较基线下降40%风险升高相关(HR 1.25)。
- 高VIM与血清肌酐翻倍(HR 1.34)和CKD 3期(HR 1.36)风险升高相关。
- 校正随访协变量后,VIM与中度及重度白蛋白尿的关联未保持显著。
核心结论
- 在1型糖尿病患者中,体重循环与肾脏事件风险升高显著相关,且不依赖于体重指数和传统危险因素。
研究设计与样本
- 对DCCT/EDIC研究中1432例参与者进行回顾性分析,基于DCCT随访期间(6±2年)的体重测量计算4项个体内体重变异指数,以VIM为主要指标,在DCCT/EDIC随访期间(21±4年)评估6项CKD进展标准。
主要发现
- 高VIM与eGFR较基线下降40%的发生率显著相关(HR 1.25;95%CI 1.09-1.41;P=.001)。
- 高VIM与基线血清肌酐翻倍显著相关(HR 1.34;95%CI 1.13-1.57;P=.001)。
- 高VIM与CKD 3期显著相关(HR 1.36;95%CI 1.12-1.63;P=.002)。
- 高VIM与eGFR年下降>3 mL/min/m2显著相关,所有分析均校正基线和随访时CKD危险因素及肾保护药物使用。
- VIM与中度及重度白蛋白尿的发生率相关,但校正随访协变量后关联未保持显著;其他体重循环指数观察到类似结果。
关键数值与推荐
- 以VIM为主要指标,按指数Z评分的1个标准差计算Cox分析的风险比(HR)。
- 研究评估6项CKD进展标准,包括eGFR较基线下降40%、基线血清肌酐翻倍、CKD 3期、eGFR年下降>3 mL/min/m2以及中度及重度白蛋白尿。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Intraindividual body-weight variability or cycling is associated with increased risk of chronic kidney disease (CKD) in the general population. OBJECTIVE: We conducted a retrospective analysis of data from the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) studies to assess association between body-weight cycling and the risk of renal events in type 1 diabetes. METHODS: Four indices of intraindividual body-weight variability were calculated for 1432 participants of DCCT/EDIC taking into account body-weight measurements during the DCCT follow-up (6 ± 2 years). Variability independent of the mean (VIM) was the main index. Six criteria of progression to CKD were studied during DCCT/EDIC follow-up (21 ± 4 years). Hazard ratio (HR) with 95% confidence interval (CI) were computed in Cox analyses for 1 SD of the indices expressed as Z-score. RESULTS: A high VIM was significantly associated with the incidence of a 40% decline in eGFR from baseline values (HR, 1.25; 95% CI, 1.09-1.41; P = .001), doubling of baseline serum creatinine (HR, 1.34; 95% CI, 1.13-1.57; P = .001), CKD stage 3 (HR, 1.36; 95% CI, 1.12-1.63; P = .002), and with a decline in eGFR > 3 mL/min/m2 per year (all analyses adjusted for CKD risk factors at baseline and follow-up, and use of nephroprotective drugs). VIM was also associated with the incidence of moderately and severely increased albuminuria, but associations did not remain significant following adjustment for follow-up covariates. Similar results were observed for the other indices of body-weight cycling. CONCLUSION: Body-weight cycling is significantly associated with an increased risk of kidney events in people with type 1 diabetes, regardless of body mass index and traditional risk factors.
引用
- Camoin M, Mohammedi K, Saulnier PJ, et al. Body-weight Cycling and Risk of Diabetic Kidney Disease in People With Type 1 Diabetes in the DCCT/EDIC Population. J Clin Endocrinol Metab. 2025. PMID: 39902910. doi:10.1210/clinem/dgae852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。